NO314588B1 - HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV - Google Patents

HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV Download PDF

Info

Publication number: NO314588B1
Authority: NO; Norway
Prior art keywords: xaa; seq; ser; gly; leu
Prior art date: 2000-09-04

Application number

NO20004413A

Other languages

English (en)

Norwegian (no)

Other versions

NO20004413D0 (no

NO20004413L (no

Inventor

Birger Soerensen

Original Assignee

Bionor Immuno As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-04

Filing date

2000-09-04

Publication date

2003-04-14

2000-09-04 Application filed by Bionor Immuno As filed Critical Bionor Immuno As

2000-09-04 Priority to NO20004413A priority Critical patent/NO314588B1/no

2000-09-04 Publication of NO20004413D0 publication Critical patent/NO20004413D0/no

2001-09-03 Priority to EA200300336A priority patent/EA006308B1/ru

2001-09-03 Priority to AT01961444T priority patent/ATE406380T1/de

2001-09-03 Priority to AU2001282706A priority patent/AU2001282706B2/en

2001-09-03 Priority to US10/129,331 priority patent/US7009037B2/en

2001-09-03 Priority to CNA2006101517487A priority patent/CN101104636A/zh

2001-09-03 Priority to NZ524556A priority patent/NZ524556A/en

2001-09-03 Priority to ES01961444T priority patent/ES2312465T3/es

2001-09-03 Priority to HK04102846.8A priority patent/HK1059940B/xx

2001-09-03 Priority to JP2002525174A priority patent/JP2004508381A/ja

2001-09-03 Priority to EP07014954A priority patent/EP1878742A3/de

2001-09-03 Priority to CA002421193A priority patent/CA2421193A1/en

2001-09-03 Priority to ZA200301740A priority patent/ZA200301740B/en

2001-09-03 Priority to HU0303134A priority patent/HUP0303134A3/hu

2001-09-03 Priority to EP01961444A priority patent/EP1322665B1/de

2001-09-03 Priority to AU8270601A priority patent/AU8270601A/xx

2001-09-03 Priority to DE60135564T priority patent/DE60135564D1/de

2001-09-03 Priority to BR0114036-1A priority patent/BR0114036A/pt

2001-09-03 Priority to NZ535148A priority patent/NZ535148A/en

2001-09-03 Priority to SK402-2003A priority patent/SK287917B6/sk

2001-09-03 Priority to CNB018157424A priority patent/CN1282656C/zh

2001-09-03 Priority to PCT/NO2001/000362 priority patent/WO2002020554A2/en

2001-09-04 Priority to MYPI20014139A priority patent/MY136081A/en

2001-09-04 Priority to ARP010104196A priority patent/AR033998A1/es

2002-03-05 Publication of NO20004413L publication Critical patent/NO20004413L/no

2003-04-14 Publication of NO314588B1 publication Critical patent/NO314588B1/no

2005-08-26 Priority to US11/211,576 priority patent/US7612168B2/en

2007-06-13 Priority to AU2007202739A priority patent/AU2007202739B2/en

2008-12-03 Priority to ARP080105262A priority patent/AR071262A2/es

2011-06-08 Priority to JP2011128389A priority patent/JP2011219481A/ja

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 103
102000004196 processed proteins & peptides Human genes 0.000 title claims description 52
239000000427 antigen Substances 0.000 title claims description 33
108091007433 antigens Proteins 0.000 title claims description 33
102000036639 antigens Human genes 0.000 title claims description 33
229960005486 vaccine Drugs 0.000 title claims description 33
238000000034 method Methods 0.000 title claims description 10
238000003018 immunoassay Methods 0.000 title claims description 7
239000000203 mixture Substances 0.000 title claims description 5
150000001413 amino acids Chemical class 0.000 claims description 40
238000002360 preparation method Methods 0.000 claims description 26
239000002671 adjuvant Substances 0.000 claims description 19
101710147327 Calcineurin B homologous protein 1 Proteins 0.000 claims description 18
101710205625 Capsid protein p24 Proteins 0.000 claims description 18
101710177166 Phosphoprotein Proteins 0.000 claims description 18
101710149279 Small delta antigen Proteins 0.000 claims description 18
241000725303 Human immunodeficiency virus Species 0.000 claims description 17
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 16
102000004169 proteins and genes Human genes 0.000 claims description 16
108090000623 proteins and genes Proteins 0.000 claims description 16
125000003275 alpha amino acid group Chemical group 0.000 claims description 13
150000001408 amides Chemical class 0.000 claims description 10
238000001514 detection method Methods 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
239000000470 constituent Substances 0.000 claims description 5
230000003308 immunostimulating effect Effects 0.000 claims description 5
108010028921 Lipopeptides Proteins 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
239000002502 liposome Substances 0.000 claims description 4
238000012986 modification Methods 0.000 claims description 4
230000004048 modification Effects 0.000 claims description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
210000001124 body fluid Anatomy 0.000 claims description 3
239000010839 body fluid Substances 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 3
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
239000008223 sterile water Substances 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
238000009472 formulation Methods 0.000 claims 1
235000001014 amino acid Nutrition 0.000 description 34
238000004128 high performance liquid chromatography Methods 0.000 description 19
230000015572 biosynthetic process Effects 0.000 description 18
238000003786 synthesis reaction Methods 0.000 description 18
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
208000031886 HIV Infections Diseases 0.000 description 15
238000004458 analytical method Methods 0.000 description 15
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
238000004989 laser desorption mass spectroscopy Methods 0.000 description 12
238000004949 mass spectrometry Methods 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
239000000243 solution Substances 0.000 description 12
208000030507 AIDS Diseases 0.000 description 11
238000011161 development Methods 0.000 description 11
239000007858 starting material Substances 0.000 description 11
210000004027 cell Anatomy 0.000 description 9
239000002245 particle Substances 0.000 description 9
229920001223 polyethylene glycol Polymers 0.000 description 9
101710104359 F protein Proteins 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
239000000969 carrier Substances 0.000 description 6
239000012458 free base Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
239000006249 magnetic particle Substances 0.000 description 6
229960000583 acetic acid Drugs 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
230000004044 response Effects 0.000 description 5
241000700605 Viruses Species 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
101710177291 Gag polyprotein Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101710125418 Major capsid protein Proteins 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
239000000047 product Substances 0.000 description 3
229940021993 prophylactic vaccine Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
229940021747 therapeutic vaccine Drugs 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
229940033330 HIV vaccine Drugs 0.000 description 2
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
210000001106 artificial yeast chromosome Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
108700004025 env Genes Proteins 0.000 description 2
101150030339 env gene Proteins 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
235000012976 tarts Nutrition 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
ANAZDOWEOOFEET-UHFFFAOYSA-N (4-hydroxyphenyl) [4-(3-oxo-1h-2-benzofuran-1-yl)phenyl] hydrogen phosphate Chemical compound C1=CC(O)=CC=C1OP(O)(=O)OC1=CC=C(C2C3=CC=CC=C3C(=O)O2)C=C1 ANAZDOWEOOFEET-UHFFFAOYSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000178270 Canarypox virus Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101710114816 Gene 41 protein Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
229940037003 alum Drugs 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000006229 carbon black Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003749 cleanliness Effects 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
101150098622 gag gene Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
108010032806 molgramostim Proteins 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000016379 mucosal immune response Effects 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
231100000654 protein toxin Toxicity 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
239000013598 vector Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
AIDS & HIV (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Extraction Or Liquid Replacement (AREA)
Medicinal Preparation (AREA)

NO20004413A 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV NO314588B1 (no)

Priority Applications (28)

Application Number	Priority Date	Filing Date	Title
NO20004413A NO314588B1 (no)	2000-09-04	2000-09-04	HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
PCT/NO2001/000362 WO2002020554A2 (en)	2000-09-04	2001-09-03	Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
EP01961444A EP1322665B1 (de)	2000-09-04	2001-09-03	Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen
AU8270601A AU8270601A (en)	2000-09-04	2001-09-03	Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
AU2001282706A AU2001282706B2 (en)	2000-09-04	2001-09-03	HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines
US10/129,331 US7009037B2 (en)	2000-09-04	2001-09-03	Modified HIV-1gag p17 peptide and immunogenic composition
CNA2006101517487A CN101104636A (zh)	2000-09-04	2001-09-03	来自gag p17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
NZ524556A NZ524556A (en)	2000-09-04	2001-09-03	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ES01961444T ES2312465T3 (es)	2000-09-04	2001-09-03	Peptidos de vih de regiones conservadas en gag p17 y sus aplicaciones, tales como vacunas.
HK04102846.8A HK1059940B (en)	2000-09-04	2001-09-03	Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
JP2002525174A JP2004508381A (ja)	2000-09-04	2001-09-03	Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法
EP07014954A EP1878742A3 (de)	2000-09-04	2001-09-03	HIV-Peptide, -Antigene, -Impfstoffzusammensetzungen und -Immunoassay sowie Verfahren zur Erkennung von durch HIV induzierten Antikörpern
CA002421193A CA2421193A1 (en)	2000-09-04	2001-09-03	Hiv peptides, antigens, vaccine compositions,immunoassay kit and a method of detecting antibodies induced by hiv
ZA200301740A ZA200301740B (en)	2000-09-04	2001-09-03	HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines.
HU0303134A HUP0303134A3 (en)	2000-09-04	2001-09-03	Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
EA200300336A EA006308B1 (ru)	2000-09-04	2001-09-03	Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
BR0114036-1A BR0114036A (pt)	2000-09-04	2001-09-03	Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
CNB018157424A CN1282656C (zh)	2000-09-04	2001-09-03	来自gagp17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
DE60135564T DE60135564D1 (de)	2000-09-04	2001-09-03	Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen
NZ535148A NZ535148A (en)	2000-09-04	2001-09-03	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
SK402-2003A SK287917B6 (sk)	2000-09-04	2001-09-03	Peptide derived from HIV-1gag p17, antigen comprising the peptide and use thereof, vaccine composition, antibody, nucleic acid, expression vector and host cell
AT01961444T ATE406380T1 (de)	2000-09-04	2001-09-03	Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen
ARP010104196A AR033998A1 (es)	2000-09-04	2001-09-04	Peptidos de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih
MYPI20014139A MY136081A (en)	2000-09-04	2001-09-04	Modified hiv - 1gag p17 peptide and immunogenic composition
US11/211,576 US7612168B2 (en)	2000-09-04	2005-08-26	Modified HIV peptides, antigens, compositions, immunoassay kit and a method of detecting antibodies induced by HIV
AU2007202739A AU2007202739B2 (en)	2000-09-04	2007-06-13	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ARP080105262A AR071262A2 (es)	2000-09-04	2008-12-03	Peptidos derivados de una proteina de vih-1gagp24, composiciones de vacunas kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih
JP2011128389A JP2011219481A (ja)	2000-09-04	2011-06-08	Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NO20004413A NO314588B1 (no)	2000-09-04	2000-09-04	HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV

Publications (3)

Publication Number	Publication Date
NO20004413D0 NO20004413D0 (no)	2000-09-04
NO20004413L NO20004413L (no)	2002-03-05
NO314588B1 true NO314588B1 (no)	2003-04-14

Family

ID=19911533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20004413A NO314588B1 (no)	2000-09-04	2000-09-04	HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV

Country Status (19)

Country	Link
US (2)	US7009037B2 (de)
EP (2)	EP1322665B1 (de)
JP (2)	JP2004508381A (de)
CN (2)	CN101104636A (de)
AR (2)	AR033998A1 (de)
AT (1)	ATE406380T1 (de)
AU (3)	AU8270601A (de)
BR (1)	BR0114036A (de)
CA (1)	CA2421193A1 (de)
DE (1)	DE60135564D1 (de)
EA (1)	EA006308B1 (de)
ES (1)	ES2312465T3 (de)
HU (1)	HUP0303134A3 (de)
MY (1)	MY136081A (de)
NO (1)	NO314588B1 (de)
NZ (2)	NZ524556A (de)
SK (1)	SK287917B6 (de)
WO (1)	WO2002020554A2 (de)
ZA (1)	ZA200301740B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL150961A0 (en)	2000-02-04	2003-02-12	Univ Duke	Human immunodeficiency virus vaccine
EP2045282B1 (de) *	2005-08-26	2011-03-23	Novo Nordisk A/S	Verfahren zur Modifizierung von Polymeren
DE602006005686D1 (de) *	2005-08-26	2009-04-23	Novo Nordisk As	Verfahren zur modifizierung eines makromolekularen systems
FI120376B (fi) *	2007-01-17	2009-09-30	Next Biomed Technologies Nbt O	Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi)	2007-03-07	2009-09-30	Next Biomed Technologies Nbt O	Menetelmä fuusiopolypeptidin valmistamiseksi
EP2344143A1 (de)	2008-09-09	2011-07-20	Mukesh Harilal Shukla	Biologisch wirksame zusammensetzung zur behandlung von hiv/aids, herstellungsverfahren und anwendung
US20100183558A1 (en)	2008-10-17	2010-07-22	Zhennan Lai	Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US9910040B2 (en)	2012-07-09	2018-03-06	Sevident, Inc.	Molecular nets comprising capture agents and linking agents
US9733242B2 (en)	2012-10-07	2017-08-15	Sevident, Inc.	Devices for capturing analyte
FR2957933B1 (fr) *	2010-03-24	2012-04-27	Seppic Sa	Vaccin vivant pour maladies aviaires
WO2011119920A2 (en)	2010-03-25	2011-09-29	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
AU2012204955B2 (en) *	2011-01-06	2016-10-06	Bionor Immuno As	Monomeric and multimeric immunogenic peptides
SMT201800284T1 (it)	2011-06-10	2018-07-17	Univ Oregon Health & Science	Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (de)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de)	2011-10-27	2013-05-01	Christopher L. Parks	Von einem eingehüllten Virus abgeleitete Virenpartikel
MX2014014683A (es)	2012-06-06	2015-02-24	Bionor Immuno As	Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
CN105102427B (zh)	2013-03-21	2018-09-07	赛诺菲-安万特德国有限公司	含有环状酰亚胺的肽产物的合成
HUE034308T2 (en)	2013-03-21	2018-02-28	Sanofi Aventis Deutschland	Preparation of hydantoin-containing peptide products
EP2848937A1 (de)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
WO2017007994A1 (en)	2015-07-08	2017-01-12	American Gene Technologies International Inc.	Hiv pre-immunization and immunotherapy
US10137144B2 (en)	2016-01-15	2018-11-27	American Gene Technologies International Inc.	Methods and compositions for the activation of gamma-delta T-cells
CN111569090A (zh)	2016-01-15	2020-08-25	美国基因技术国际有限公司	用于活化γ-δ T细胞的方法和组合物
JP7153332B2 (ja)	2016-02-08	2022-10-14	アメリカンジーンテクノロジーズインターナショナルインコーポレイテッド	Ｈｉｖワクチン接種および免疫療法
ES2911448T3 (es)	2016-03-09	2022-05-19	American Gene Tech Int Inc	Vectores combinados y métodos para el tratamiento del cáncer
US11976292B2 (en)	2016-06-08	2024-05-07	American Gene Technologies International Inc.	Non-integrating viral delivery system and methods related thereto
EP3481418A4 (de)	2016-07-08	2020-03-11	American Gene Technologies International Inc.	Hiv-vorimmunisierung und -immuntherapie
US11583562B2 (en)	2016-07-21	2023-02-21	American Gene Technologies International Inc.	Viral vectors for treating Parkinson's disease
JP2020512815A (ja)	2017-04-03	2020-04-30	アメリカンジーンテクノロジーズインターナショナルインコーポレイテッド	フェニルケトン尿症を処置するための組成物および方法
WO2018232359A1 (en)	2017-06-16	2018-12-20	American Gene Technologies International Inc.	Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
US11352646B2 (en)	2018-11-05	2022-06-07	American Gene Technologies International Inc.	Vector system for expressing regulatory RNA
RU2727673C1 (ru) *	2019-08-09	2020-07-22	Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства	Антитела против белка р17 ВИЧ-1 субтипа А
GB2610556A (en) *	2021-09-02	2023-03-15	113 Botanicals Ltd	Extraction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ235538A (en) *	1989-10-12	1992-06-25	Viral Technologies Inc	Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
SE468168B (sv)	1990-02-20	1992-11-16	Replico Medical Ab	Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
DE4039925A1 (de) *	1990-12-14	1992-06-17	Behringwerke Ag	Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
SE9101863D0 (sv) *	1991-06-13	1991-06-13	Replico Medical Ab	Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
WO1998029551A1 (en)	1997-01-02	1998-07-09	Universidade Federal De Minas Gerais	THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN HYBRID PROTEIN (p24/p17) DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUSES (HIV-1)
GB9703802D0 (en) *	1997-02-24	1997-04-16	Kingsman Susan M	Anti-hiv peptides and proteins
US5972339A (en)	1997-11-13	1999-10-26	The General Hospital Corporation	Method of eliciting anti-HIV-1 helper T cell responses
US6534482B1 (en) *	1998-05-13	2003-03-18	Epimmune, Inc.	Expression vectors for stimulating an immune response and methods of using the same
NO311807B1 (no)	1999-03-04	2002-01-28	Bionor Immuno As	HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

2000
- 2000-09-04 NO NO20004413A patent/NO314588B1/no not_active IP Right Cessation
2001
- 2001-09-03 JP JP2002525174A patent/JP2004508381A/ja active Pending
- 2001-09-03 SK SK402-2003A patent/SK287917B6/sk not_active IP Right Cessation
- 2001-09-03 US US10/129,331 patent/US7009037B2/en not_active Expired - Fee Related
- 2001-09-03 AU AU8270601A patent/AU8270601A/xx active Pending
- 2001-09-03 CN CNA2006101517487A patent/CN101104636A/zh active Pending
- 2001-09-03 AT AT01961444T patent/ATE406380T1/de not_active IP Right Cessation
- 2001-09-03 DE DE60135564T patent/DE60135564D1/de not_active Expired - Lifetime
- 2001-09-03 HU HU0303134A patent/HUP0303134A3/hu unknown
- 2001-09-03 CN CNB018157424A patent/CN1282656C/zh not_active Expired - Fee Related
- 2001-09-03 ZA ZA200301740A patent/ZA200301740B/en unknown
- 2001-09-03 ES ES01961444T patent/ES2312465T3/es not_active Expired - Lifetime
- 2001-09-03 BR BR0114036-1A patent/BR0114036A/pt not_active IP Right Cessation
- 2001-09-03 EP EP01961444A patent/EP1322665B1/de not_active Expired - Lifetime
- 2001-09-03 NZ NZ524556A patent/NZ524556A/en not_active IP Right Cessation
- 2001-09-03 EA EA200300336A patent/EA006308B1/ru not_active IP Right Cessation
- 2001-09-03 CA CA002421193A patent/CA2421193A1/en not_active Abandoned
- 2001-09-03 EP EP07014954A patent/EP1878742A3/de not_active Withdrawn
- 2001-09-03 AU AU2001282706A patent/AU2001282706B2/en not_active Ceased
- 2001-09-03 NZ NZ535148A patent/NZ535148A/en not_active IP Right Cessation
- 2001-09-03 WO PCT/NO2001/000362 patent/WO2002020554A2/en not_active Ceased
- 2001-09-04 MY MYPI20014139A patent/MY136081A/en unknown
- 2001-09-04 AR ARP010104196A patent/AR033998A1/es active IP Right Grant
2005
- 2005-08-26 US US11/211,576 patent/US7612168B2/en not_active Expired - Fee Related
2007
- 2007-06-13 AU AU2007202739A patent/AU2007202739B2/en not_active Ceased
2008
- 2008-12-03 AR ARP080105262A patent/AR071262A2/es not_active Application Discontinuation
2011
- 2011-06-08 JP JP2011128389A patent/JP2011219481A/ja active Pending

Also Published As

Publication number	Publication date
NZ535148A (en)	2007-06-29
EP1878742A2 (de)	2008-01-16
EP1322665A2 (de)	2003-07-02
SK4022003A3 (en)	2003-09-11
EA200300336A1 (ru)	2003-08-28
HUP0303134A3 (en)	2012-09-28
SK287917B6 (sk)	2012-03-02
ES2312465T3 (es)	2009-03-01
NO20004413D0 (no)	2000-09-04
US20040115615A1 (en)	2004-06-17
CN1282656C (zh)	2006-11-01
US20070237783A1 (en)	2007-10-11
NO20004413L (no)	2002-03-05
US7612168B2 (en)	2009-11-03
JP2011219481A (ja)	2011-11-04
NZ524556A (en)	2005-01-28
US7009037B2 (en)	2006-03-07
AU2001282706B2 (en)	2007-03-22
CN101104636A (zh)	2008-01-16
AU2007202739A1 (en)	2007-07-05
MY136081A (en)	2008-08-29
ZA200301740B (en)	2004-06-21
AU8270601A (en)	2002-03-22
BR0114036A (pt)	2003-07-22
CN1460111A (zh)	2003-12-03
EP1322665B1 (de)	2008-08-27
HUP0303134A2 (hu)	2005-03-29
EA006308B1 (ru)	2005-10-27
CA2421193A1 (en)	2002-03-14
WO2002020554A3 (en)	2002-06-13
JP2004508381A (ja)	2004-03-18
EP1878742A3 (de)	2008-04-30
AR033998A1 (es)	2004-01-21
WO2002020554A2 (en)	2002-03-14
HK1059940A1 (en)	2004-07-23
ATE406380T1 (de)	2008-09-15
AR071262A2 (es)	2010-06-09
DE60135564D1 (de)	2008-10-09
AU2007202739B2 (en)	2009-12-03

Legal Events

Date	Code	Title	Description
2013-04-22	MM1K	Lapsed by not paying the annual fees